This is the single most reliable indicator of fat loss in this phase
The key is maintaining that seven-day interval to keep blood levels stable and appetite suppression consistent
Walk into our clinic in Boca Raton, 9250 Glades Rd #110
Ozeki et al (2022) found that GLP1-RA semaglutide effectively reduces body adiposity while maintaining the skeletal muscle mass in obese Type 2 Diabetic patients. Xiang et al (2023) had similar findings, semaglutide can reduce the weight and fat of obese patients while effectively maintaining muscle mass and muscle strength. Chen et al (2023) conducted a 3-month intervention using dulaglutide in patients with Type 2 Diabetes, noting , dulaglutide intervention does not cause muscle and bone mass loss while inducing weight loss, and % change in body fat was independently associated with improved glucose control during dulaglutide therapy. With an increasing number of physicians and researchers relying on GLP-1 therapies for clinical care and research, it will continue to be crucial to track sensitive changes in body composition across different patient populations
doi: 10.1016/j.celrep.2019.05.055
However, co-formulations of amylin with insulin are currently in development, as is the possibility of use of pramlintide in pumps or artificial pancreas systems
